176 related articles for article (PubMed ID: 35924575)
1. Early expression of CD94 and loss of CD96 on CD8+ T cells after allogeneic stem cell tranplantation is predictive of subsequent relapse and survival.
Verma K; Croft W; Pearce H; Zuo J; Stephens C; Nunnick J; Kinsella FA; Malladi R; Moss P
Haematologica; 2023 Feb; 108(2):433-443. PubMed ID: 35924575
[TBL] [Abstract][Full Text] [Related]
2. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.
Zhou J; Bashey A; Zhong R; Corringham S; Messer K; Pu M; Ma W; Chut T; Soiffer R; Mitrovich RC; Lowy I; Ball ED
Biol Blood Marrow Transplant; 2011 May; 17(5):682-92. PubMed ID: 20713164
[TBL] [Abstract][Full Text] [Related]
3. Expansion of natural killer cell receptor (CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit.
Tanaka J; Sugita J; Kato N; Toubai T; Ibata M; Shono Y; Ota S; Kondo T; Kobayashi T; Kobayashi M; Asaka M; Imamura M
Exp Hematol; 2007 Oct; 35(10):1562-6. PubMed ID: 17681668
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Infusion of donor-derived CD8
Muffly L; Sheehan K; Armstrong R; Jensen K; Tate K; Rezvani AR; Miklos D; Arai S; Shizuru J; Johnston L; Meyer E; Weng WK; Laport GG; Negrin RS; Strober S; Lowsky R
Blood Adv; 2018 Mar; 2(6):681-690. PubMed ID: 29572391
[TBL] [Abstract][Full Text] [Related]
6. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
[TBL] [Abstract][Full Text] [Related]
7. Early CD8+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT.
Ranti J; Kurki S; Salmenniemi U; Putkonen M; Salomäki S; Itälä-Remes M
PLoS One; 2018; 13(9):e0204136. PubMed ID: 30235281
[TBL] [Abstract][Full Text] [Related]
8. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M
Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638
[TBL] [Abstract][Full Text] [Related]
9. Cord blood graft composition impacts the clinical outcome of allogeneic stem cell transplantation.
Wikell H; Ponandai-Srinivasan S; Mattsson J; Gertow J; Uhlin M
Transpl Infect Dis; 2014 Apr; 16(2):203-12. PubMed ID: 24456214
[TBL] [Abstract][Full Text] [Related]
10. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
Front Immunol; 2019; 10():1997. PubMed ID: 31507601
[TBL] [Abstract][Full Text] [Related]
11. TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation.
Moatti A; Debesset A; Pilon C; Beldi-Ferchiou A; Leclerc M; Redjoul R; Charlotte F; To NH; Bak A; Belkacemi Y; Salomon BL; Issa F; Michonneau D; Maury S; Cohen JL; Thiolat A
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387779
[TBL] [Abstract][Full Text] [Related]
12. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
[TBL] [Abstract][Full Text] [Related]
13. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
Chapuis AG; Egan DN; Bar M; Schmitt TM; McAfee MS; Paulson KG; Voillet V; Gottardo R; Ragnarsson GB; Bleakley M; Yeung CC; Muhlhauser P; Nguyen HN; Kropp LA; Castelli L; Wagener F; Hunter D; Lindberg M; Cohen K; Seese A; McElrath MJ; Duerkopp N; Gooley TA; Greenberg PD
Nat Med; 2019 Jul; 25(7):1064-1072. PubMed ID: 31235963
[TBL] [Abstract][Full Text] [Related]
14. T cell receptor excision circle levels in CD94-expressing CD8 T Cells during graft-versus-host disease.
Sugita J; Iwao N; Tanaka J; Kato N; Shiratori S; Wakasa K; Shigematsu A; Toubai T; Takahata M; Kondo T; Asaka M; Imamura M
Leuk Lymphoma; 2008 Jul; 49(7):1306-10. PubMed ID: 18604719
[TBL] [Abstract][Full Text] [Related]
15. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
16. Expression of killer cell inhibitor receptors on immunocompetent cells with relation to graft-versus-host disease after hematopoietic stem cell transplantation.
Duan LN; Chen C; Huang SL; Fang JP; Wei J; Bao R; Li Y; Han HX; Li SN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):625-32. PubMed ID: 14706148
[TBL] [Abstract][Full Text] [Related]
17. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Avanzini MA; Maccario R; Locatelli F; Giebel S; Santos CD; Bernardo ME; Pagliara D; Montagna D; Longo S; Amendola G; Marconi M
Exp Hematol; 2006 Oct; 34(10):1429-34. PubMed ID: 16982336
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation.
Varanasi PR; Ogonek J; Luther S; Dammann E; Stadler M; Ganser A; Borchers S; Hambach L; Weissinger EM
PLoS One; 2019; 14(3):e0213739. PubMed ID: 30889204
[TBL] [Abstract][Full Text] [Related]
19. Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion.
Koster EAS; Bonneville EF; Borne PAVD; van Balen P; Marijt EWA; Tjon JML; Snijders TJF; van Lammeren D; Veelken H; Putter H; Falkenburg JHF; Halkes CJM; de Wreede LC
Front Immunol; 2023; 14():1208814. PubMed ID: 37593737
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
